• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Nutraceuticals
    • Markets
    • Health
    • Jobs
    • Events
    • Buyers' Guide
    • Showcases
    • More
  • Magazine
  • News
  • Exclusives
  • Nutraceuticals
  • Markets
  • Health
  • Jobs
  • Events
  • Buyers' Guide
  • Showcases
  • Current & Past Issues
    Features
    Columns
    Editorials
    Digital Edition
    Subscribe Now
    Advertise Now
    eNewsletter
    Editorial Guidelines
    Top Features
    How Can the Nutraceuticals Industry Empower More Women?

    The Naturally Proud Network: Supporting Diversity, Equity, and Inclusion

    Radicle Science Aims to Set New Trajectory for Healthcare with Modern Clinical Trial Model

    Key Trends in Functional Foods for 2024

    New Cognitive Health Solutions Aim to Address Varied Consumer Needs
    Breaking News
    Certifications, Approvals and Patents
    Exclusives
    Industry & Market News
    People
    Products
    Regulatory
    Glossary
    Research
    Supplier News
    Supplier Insights
    Live From Shows
    Top News
    Ahiflower Replaces Key Tissue DHA in Mice Comparably to Marine DHA

    Chromadex’s Niagen NR Tested in Phase 1 Parkinson's Study

    Alkemist Announces New Participants in its Transparency Program

    One Hemp Coalition Forms to Advocate for CBD Regulatory Standards

    Earthlight Whole Food Vitamin D Receives Food, Beverage Approval in Brazil
    Exclusives
    Top Companies
    Blogs & Guest Articles
    Health E-Insights
    Area Code 420
    eBook
    Antioxidants
    Dairy-Based Ingredients
    Enzymes
    Fatty Acids
    Fiber & Carbohydrates
    Green Foods
    Herbs & Botanicals
    Marine Nutraceuticals
    Minerals
    Omega 3s
    Probiotics & Prebiotics
    Proteins, Peptides, Amino Acids
    Sweeteners
    Vitamins

    Ahiflower Replaces Key Tissue DHA in Mice Comparably to Marine DHA

    One Hemp Coalition Forms to Advocate for CBD Regulatory Standards

    Earthlight Whole Food Vitamin D Receives Food, Beverage Approval in Brazil

    FDA’s Safety Review of NAC to Go Under Peer Review

    Gnosis by Lesaffre Launches Private-Label Immune Support Supplement MenaQ7 Protect
    Consumer Trends
    Contract Manufacturing
    Cosmeceuticals / Nutricosmetics
    Delivery & Dosage Technologies
    Dietary Supplements
    Flavors & Colors
    Functional Foods & Beverages
    Healthcare Trends
    Medical Nutrition
    Mergers & Acquisitions
    Natural/Organic
    Nutrition Bars
    Packaging
    Pet Nutraceuticals
    Quality & Safety
    Regulations
    Research
    Testing
    World Markets

    Ahiflower Replaces Key Tissue DHA in Mice Comparably to Marine DHA

    Chromadex’s Niagen NR Tested in Phase 1 Parkinson's Study

    How Can the Nutraceuticals Industry Empower More Women?

    Alkemist Announces New Participants in its Transparency Program

    One Hemp Coalition Forms to Advocate for CBD Regulatory Standards
    Bone & Joint Health
    Cancer Risk
    Cardiovascular Health
    Cognitive Function
    Diabetes & Blood Sugar Management
    Digestive Health
    Energy
    Eye Health
    Healthy Aging
    Immune Function
    Infant & Children's Health
    Inflammation
    Men's Health
    Mood Health & Sleep
    Oral Health
    Sexual & Reproductive Health
    Skin Health
    Sports Nutrition
    Weight Management/Weight Loss
    Women's Health

    How Can the Nutraceuticals Industry Empower More Women?

    Pharmavite Acquires Women’s Health Brand Bonafide for $425 Million

    Kyowa Hakko Discussed Cognitive Health Supplements at Neuro Navigators Event

    Gnosis by Lesaffre Launches Private-Label Immune Support Supplement MenaQ7 Protect

    Beauty Brand Genaura to Launch Product Line Featuring Gencor’s Levagen+
    Industry Events
    Live From Show Events
    Webinars
    All Companies
    Categories
    Trade Associations
    Company Capabilities
    International Buyers Guide Companies
    Aiya America, Inc. (Aiya Matcha)

    BGG World

    PhytoGaia Inc

    JRS Pharma

    Sabinsa Corporation
    Companies
    Product Releases
    News Releases
    Literature / Brochures
    White Papers
    Jobs
    VIdeos
    Services
    Add New Company
    International Buyers Guide Companies
    Aiya America, Inc. (Aiya Matcha)

    BGG World

    PhytoGaia Inc

    JRS Pharma

    Sabinsa Corporation
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • All Companies
      • Categories
      • Trade Associations
      • Company Capabilities
    • Nutraceuticals
      • Antioxidants
      • Dairy-Based Ingredients
      • Enzymes
      • Fatty Acids
      • Fiber & Carbohydrates
      • Green Foods
      • Herbs & Botanicals
      • Marine Nutraceuticals
      • Minerals
      • Omega 3s
      • Probiotics & Prebiotics
      • Proteins, Peptides, Amino Acids
      • Sweeteners
      • Vitamins
    • Markets
      • Consumer Trends
      • Contract Manufacturing
      • Cosmeceuticals / Nutricosmetics
      • Delivery & Dosage Technologies
      • Dietary Supplements
      • Flavors & Colors
      • Functional Foods & Beverages
      • Healthcare Trends
      • Medical Nutrition
      • Mergers & Acquisitions
      • Natural/Organic
      • Nutrition Bars
      • Packaging
      • Pet Nutraceuticals
      • Quality & Safety
      • Regulations
      • Research
      • Testing
      • World Markets
    • Health
      • Bone & Joint Health
      • Cancer Risk
      • Cardiovascular Health
      • Cognitive Function
      • Diabetes & Blood Sugar Management
      • Digestive Health
      • Energy
      • Eye Health
      • Healthy Aging
      • Immune Function
      • Infant & Children's Health
      • Inflammation
      • Men's Health
      • Mood Health & Sleep
      • Oral Health
      • Sexual & Reproductive Health
      • Skin Health
      • Sports Nutrition
      • Weight Management/Weight Loss
      • Women's Health
    • Online Exclusives
    • Webinars
    • Slideshows
    • Blogs & Guest Articles
    • Health E-Insights
    • Videos
    • Podcasts
    • Infographics
    • eBook
    • Whitepapers
    • Top Companies
    • Research
      • TrendSense
      • Monograph Center
      • White Papers
      • Research News
    • Jobs
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Supplier Showcases
      • Companies
      • Product Releases
      • News Releases
      • Literature / Brochures
      • White Papers
      • Jobs
      • VIdeos
      • Services
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Medical Foods Regulation: FDA’s Restrictive View Stifles Innovation

    The present regulatory scheme is out of date and requires significant revisions to reflect modern realities.

    Medical Foods Regulation: FDA’s Restrictive View Stifles Innovation
    By Todd Harrison, Venable11.01.17
    In recent years, we have seen a proliferation of dietary supplement and functional food products being marketed as medical foods. Some of these products appear to have legitimate basis as they target populations with distinct nutritive needs. On the other hand, we have also seen significant growth in dietary supplement products masquerading as “medical foods,” consequently putting a vulnerable and unsuspecting public at risk. 

    Many of these products are targeting vulnerable patient populations, in particular the elderly, with claims related to Alzheimer’s, osteoarthritis, rheumatoid arthritis, and stroke. These products do not appear on their face to relate to “the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.” (21 U.S.C. § 360ee(b)(3).)

    Rather, they appear positioned to justify the use of otherwise impermissible disease claims for dietary supplements. The FDA does not appear to believe there’s a need to address these products in a decisive manner. Rather, it continues to allow this pseudo-product category to grow, placing certain vulnerable patient populations at risk.

    To be sure, there is a valid place for legitimate medical food products that are based on sound nutritional science and clinical research. Indeed, given the breadth of claims the FDA believes are impermissible disease claims, it makes sense to expand those products that are rightfully considered to be appropriate options for many diseases that have clear nutritional underpinnings. Moreover, FDA’s narrow definition of a medical food excludes products that would be particularly beneficial to certain patient populations, including those with type 2 diabetes, Irritable Bowel Syndrome (IBS), and male fertility issues related to oxidative stress.  

    FDA’s overly restrictive view of what is considered a medical food is particularly troublesome. Without going into detail about FDA’s fatally restrictive position on medical foods, it is important to understand what the statutory framework for the Orphan Drug Act requires:

    • The product must be used under the supervision of a physician.
    • The substance must be recognized as a “food.” (Dietary supplements are foods under the Federal Food, Drug and Cosmetic Act.)
    • The product must be a food that is specifically formulated to be consumed enterally (taken by mouth).
    • The medical food must be for the “specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.” 
    Ready or Not? 
    Over the years I have discussed how certain diseases or health-related conditions are ripe for medical foods, yet FDA does not believe this to be true. For instance, if there was ever a classic disease related to nutrition, it is type 2 diabetes or metabolic syndrome. (There is still some question whether FDA considers metabolic syndrome a disease or not.) The first intervention is not a prescription drug but lifestyle changes to maintain normal blood sugar levels. However, simply altering the diet is not necessarily an easy proposition, so it makes sense to permit targeted dietary ingredients in this definition.

    But how does a particular dietary ingredient meet this need if it is not based on what we would normally consider a nutritive effect? This may be more easily accomplished for those with IBS than type 2 diabetes. The literature is replete with the benefits of probiotics for IBS patients and the benefits of probiotics should be considered nutritive not pharmacological.

    Yet, FDA takes the position that probiotics are not appropriate medical foods for the dietary management of IBS. This position is likely related to the fact that individuals can do their own research and take a probiotic supplement, which is a simple modification to the diet. This interpretation strains credulity, as most IBS patients are not going to do the research or know the proper dosage to take to help manage their symptoms. Thus, by taking a blanket position that probitiocs are is not an appropriate medical food for IBS, the agency denies patients a dietary management tool that can have profound benefits.

    Another area to consider is male reproductive health. There is mounting evidence that oxidative stress can impact the quality of male sperm. The agency takes the position this is an implied male infertility claim, which it is not, in my mind. However, if we accept the agency’s position for the purpose of this column only, why should we not be able to develop a medical food that is specifically designed to lower the impact of oxidative stress on male fertility through the use of targeted antioxidants?  

    Access Restricted
    The purpose of this column is to demonstrate that we have reached a point within the present regulatory paradigm where access to products that provide real solutions are not readily available to consumers. Moreover, the agency feels constrained to restrict medical foods and claims for dietary supplements. Yet, on the medical food front, FDA fails to go after the most egregious actors; and on the dietary supplement front, the agency wrongfully believes that oxidative stress and male fertility, for example, is an implied disease claim.

    This confluent set of events causes more companies to either strain the definition of medical foods to include osteoarthritis, or develop claims (e.g., “supports blood sugar levels already in the normal range” or “supports joint comfort”) that have little value to consumers and patients. 

    Changing the Regulatory Paradigm
    To regular readers of this column, it is known that I have been a longtime advocate (to the dismay of some) that our regulatory paradigm must evolve to be consistent with reality and common sense. Rather than viewing health as a binary proposition between disease and health, we need to understand that many things FDA considers to be a disease are actually part of the normal aging process. For instance, I recently had an MRI that disclosed a partial tear in my rotator cuff, however, it also disclosed that I have the start of osteoarthritis in my elbow and shoulder, coupled with inflammation. As my doctor made clear, “you are 55 years old and this is a common part of aging even though it has a disease moniker attached to it.”

    My rotator cuff may need to be repaired if physical therapy does not work, but the osteoarthritis will remain. Under the present paradigm, I have one of two choices for pain relief: prescription drugs or OTC drugs, all of which have serious side effects related to long-term use. However, I also admit that I do not have a distinct nutritional need for curcumin or glucosamine. So where does this leave me? Fortunately, I know what works and what does not. But the typical consumer will need to decipher code words on a dietary supplement bottle or purchase a medical food that really isn’t a medical food. This situation does not make sense.

    Here’s a simple solution. Because the industry as a whole is afraid to reopen the Dietary Supplement Health and Education Act, I have a new proposal:

    • Reopen the definition of a medical food under the Orphan Drug Act to include dietary ingredients that have nutritive value or therapeutic value;
    • Permit dietary management claims for diseases that have a significant nutritional component (e.g., type 2 diabetes, stage 1 high blood pressure, IBS);
    • Permit therapeutic claims for all other conditions that are already permitted for OTC drugs (e.g., osteoarthritis, GERD, cough/cold);
    • Restrict those products intended to provide dietary management for more serious conditions, but still manageable through dietary intervention (e.g., type 2 diabetes, IBS) to be sold behind the counter without a prescription or through physician offices;
    • Require companies to list and register with FDA;
    • Require the submission of a dossier to FDA in support of the medical food’s safety and efficacy for the intended patient population;
               - Limit FDA’s review of the dossier;
               - FDA may only object if it is clear there is no basis for the product to be marketed as a dietary supplement;
               - Setup an independent third-party review process when FDA objects. 

    It’s clear the present regulatory scheme is out of date and requires significant revisions to reflect modern realities. More and more companies are entering the medical food arena because they view it as a large loophole to disease claims. Some of these medical foods are legitimate while some are not, but regardless, FDA seems unwilling to act decisively with those that are clearly not. On the other hand, we do not want to sweep away products that are legitmate and will help a significant number of individuals improve their health. The disease/health paradigm we have created is broken and cannot address the changes in society, flow of information, and the ability of rogue companies to market any product they choose.

    Bold action is required. We are not growing healthier in this country. People are sicker because we fail to understand that not everything is a disease that requires strong pharmaceutical intervention. The latter is certainly necessary, but think of the good we could create if we gave the supplement and pharmaceutical industries a path to development of nutritive products that are lawfully sold without fear of FDA or plaintiff class action lawyers who sue companies under state law because of disease claims.

    It is time for a change. Are we as an industry willing to lead that change, or will we continue to ignore problems that the primary statutory and regulatory framework has created? My hope is the former.


    Todd Harrison
    Venable

    Todd Harrison is partner with Venable, which is located in Washington, D.C. He advises food and drug companies on a variety of FDA and FTC matters, with an emphasis on dietary supplement, functional food, biotech, legislative, adulteration, labeling and advertising issues. He can be reached at 575 7th St. NW, Washington, D.C. 20004, Tel: 202-344-4724; E-mail: taharrison@venable.com.
    Related Searches
    • Nutritional
    • Functional Food
    • Inflammation
    • Stress
    Related Knowledge Center
    • Medical Nutrition
    • Dietary Supplements
    • Regulations
    • Healthcare Trends
    Suggested For You
    Prescription Probiotics and Microbiome Modulation Prescription Probiotics and Microbiome Modulation
    G-Agmatine: An Innovative Solution for a Healthy Nervous System G-Agmatine: An Innovative Solution for a Healthy Nervous System
    Speakers Announced for Vitafoods Europe and Future of Nutrition Summit Speakers Announced for Vitafoods Europe and Future of Nutrition Summit
    Ayana Bio on Path to Scale Bioactives Derived from Plant Cell Cultures Ayana Bio on Path to Scale Bioactives Derived from Plant Cell Cultures
    Entrinsic Bioscience Expands Medical Food Line with enterade IBS-D Entrinsic Bioscience Expands Medical Food Line with enterade IBS-D
    Corn Mays Extract Linked to Sleep Quality Benefits Corn Mays Extract Linked to Sleep Quality Benefits
    Lemon Flavonoid Complex Shown to Support Healthy Blood Glucose Lemon Flavonoid Complex Shown to Support Healthy Blood Glucose
    Medical Food Addresses Fatty Acid Deficiencies, May Help Manage ADHD Symptoms Medical Food Addresses Fatty Acid Deficiencies, May Help Manage ADHD Symptoms
    Vitux AS Joins SFI Health to Develop Equazen Pro Smart Chews Supplements Vitux AS Joins SFI Health to Develop Equazen Pro Smart Chews Supplements
    Lanfam LLC Launches Medical Food for Pain Relief Lanfam LLC Launches Medical Food for Pain Relief
    High DHA, Low Linoleic Acid Medical Food Shown to Help Cognitive Recovery in Malnourished Children High DHA, Low Linoleic Acid Medical Food Shown to Help Cognitive Recovery in Malnourished Children
    Claims Spell Success in Today’s Nutritional Products Market Claims Spell Success in Today’s Nutritional Products Market
    Personalized Health & The Future of Cannabis Personalized Health & The Future of Cannabis
    UNPA Offers Education and Training for Food and Supplement Companies UNPA Offers Education and Training for Food and Supplement Companies
    CRN to Host Interactive Medical Food Summit CRN to Host Interactive Medical Food Summit

    Related Columns

    • Dietary Supplements | Healthcare Trends | Medical Nutrition | Probiotics & Prebiotics
      Prescription Probiotics and Microbiome Modulation

      Prescription Probiotics and Microbiome Modulation

      Investment and R&D in microbiome-modulation is rapidly picking up steam, and could collide with the dietary supplement market.
      By Erik Goldman, Holistic Primary Care 09.28.23

    • Dietary Supplements | Healthy Aging | Pet Nutraceuticals | Proteins, Peptides, Amino Acids
      G-Agmatine: An Innovative Solution for a Healthy Nervous System

      G-Agmatine: An Innovative Solution for a Healthy Nervous System

      Gad Gilad discusses the company’s research and its line of products that address challenges to healthy nerve function.
      By Sheldon Baker 05.01.23

    • Breaking News | Dietary Supplements | Functional Foods & Beverages | Healthcare Trends | Industry & Market News
      Speakers Announced for Vitafoods Europe and Future of Nutrition Summit

      Speakers Announced for Vitafoods Europe and Future of Nutrition Summit

      Event organizers have published the slate of scientific experts lined up for May 8-10.
      03.16.23


    • Antioxidants | Delivery & Dosage Technologies | Dietary Supplements | World Markets
      Ayana Bio on Path to Scale Bioactives Derived from Plant Cell Cultures

      Ayana Bio on Path to Scale Bioactives Derived from Plant Cell Cultures

      CEO Frank Jaksch discussed the company’s plans for commercialization, and the benefits of bypassing agricultural systems.
      By Mike Montemarano, Associate Editor 02.27.23

    • Breaking News | Digestive Health | Medical Nutrition | Products | Proteins, Peptides, Amino Acids
      Entrinsic Bioscience Expands Medical Food Line with enterade IBS-D

      Entrinsic Bioscience Expands Medical Food Line with enterade IBS-D

      Formula of amino acids and electrolytes supports digestive function while replenishing fluid loss and minerals.
      02.21.23

    Loading, Please Wait..
    Breaking News
    • Ahiflower Replaces Key Tissue DHA in Mice Comparably to Marine DHA
    • Chromadex’s Niagen NR Tested in Phase 1 Parkinson's Study
    • Alkemist Announces New Participants in its Transparency Program
    • One Hemp Coalition Forms to Advocate for CBD Regulatory Standards
    • Earthlight Whole Food Vitamin D Receives Food, Beverage Approval in Brazil
    View Breaking News >
    CURRENT ISSUE

    November 2023

    • Success Factors in Sports Nutrition
    • Key Trends in Functional Foods for 2024
    • New Cognitive Health Solutions Aim to Address Varied Consumer Needs
    • Why Women are Fleeing STEM Jobs, and How the Nutraceutical Industry Can WIN Them Back
    • Liposomal Delivery: The Future for Dietary Supplement Innovation
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Ahiflower Replaces Key Tissue DHA in Mice Comparably to Marine DHA
    Chromadex’s Niagen NR Tested in Phase 1 Parkinson's Study
    Alkemist Announces New Participants in its Transparency Program
    Coatings World

    Latest Breaking News From Coatings World

    Weekly Recap: AkzoNobel and Kansai Paint, Tnemec Top This Week’s Stories
    PPG Earns Equality 100 Award in 2023 Corporate Equality Index
    Beckers Aiming for New Industry Standard for Sustainability
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    What You’re Reading in November
    Millstone Medical Outsourcing Moves Testing Services into Expanded Facility
    Nordson Medical Expands Easton, PA Operations
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Intas Pharmaceuticals Receives Another Warning Letter from FDA
    Ono Expands Investment in Ono Venture Fund to $200M
    Sirnaomics Names Francois Lebel Chief Medical Officer
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Mary Kay Expands Operations into Hungary
    Anti-Aging Products Market to Hit $60 Billion by 2030
    Wella Company Marks 3 Years of Success—& Aims to Expand
    Happi

    Latest Breaking News From Happi

    Beverly Hills MD Sells Over 7.5 Million Units of Its Dermal Repair Complex
    Mary Kay Expands to Hungary
    Itching: Is a Common Skin Bacterium Behind It?
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: Toyo Ink, DIC, Flint Group Top This Week’s Stories
    D3 Introduces Micro Particle Jetting Technology at Formnext 2023
    Reproflex3 Invests €500,000 for Corrugated Packaging Pre-Press Capabilities
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Top stories from November
    Davis-Standard's headquarters attains ISO 14001 certification
    Abbott Label named AFFLINK preferred supplier
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Optima Packaging Group Awarded for its Digitalization Strategy
    What You’re Reading on Nonwovens-Industry.com
    ISSA Clean Advocacy Summit and Fly-In Set for April
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT’s Most Read Articles in November
    Anika's Integrity Implant System Makes its O.R. Debut
    Study Shows How a Multimodal Feedback System Can Improve Laser Surgery
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: Avery Dennison and 49ers, Linxens Top This Week’s Stories
    HYBRID Software Extends CLOUDFLOW Maker for 3D Binder Jet Applications
    Emerson Appoints Michael Tang as Chief Legal Officer

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login